Answer
Yes — the CDC/MMWR refers to dengue NS1 antigen assays and combined NS1/IgM/IgG assays as rapid diagnostic tests (RDTs) used for early dengue diagnosis. [1–1]
Framing (Guideline priority):
- CDC/MMWR describes dengue diagnostics as molecular (NAAT) and serologic, explicitly including NS1 antigen detection alongside IgM/IgG, and notes FDA-cleared assays for NS1 and IgM; these are implemented as rapid tests in practice and may be used instead of NAAT in early illness per CDC’s testing flowchart 1.
- While MMWR emphasizes assay types (NAAT, NS1 antigen EIA, IgM EIA), these are widely deployed in rapid formats; algorithm boxes allow “perform dengue virus NS1 testing instead of NAAT” in acute specimens—functionally aligning with RDT use for timely management impacting morbidity and mortality 1.
Augmenting evidence (highest quality, recent):
- Clinical studies explicitly label combined NS1/IgM/IgG cassettes as rapid diagnostic tests and show best accuracy when NS1 is combined with IgM/IgG, supporting their role as “RDTs” for early case detection and triage 2.
- Newer evaluations confirm combined NS1/IgM strategies can approach very high acute-phase sensitivity, reinforcing rapid clinical utility when molecular testing is unavailable, which supports early interventions that reduce severe outcomes and improve quality of life 3.
Pitfalls/caveats to avoid:
- Isolated IgM positivity can reflect cross-reactivity or past infection; confirm with PRNT if definitive diagnosis will change management, especially in pregnancy or co-circulation settings 1.
- Sensitivity of individual NS1 lines varies by brand and day of illness; combining with IgM/IgG improves detection across illness days 2, 4.